Identifying potential natural inhibitors of Brucella melitensis Methionyl-tRNA synthetase through an in-silico approach.
Journal
PLoS neglected tropical diseases
ISSN: 1935-2735
Titre abrégé: PLoS Negl Trop Dis
Pays: United States
ID NLM: 101291488
Informations de publication
Date de publication:
03 2022
03 2022
Historique:
received:
08
09
2021
accepted:
16
02
2022
revised:
31
03
2022
pubmed:
22
3
2022
medline:
5
4
2022
entrez:
21
3
2022
Statut:
epublish
Résumé
Brucellosis is an infectious disease caused by bacteria of the genus Brucella. Although it is the most common zoonosis worldwide, there are increasing reports of drug resistance and cases of relapse after long term treatment with the existing drugs of choice. This study therefore aims at identifying possible natural inhibitors of Brucella melitensis Methionyl-tRNA synthetase through an in-silico approach. Using PyRx 0.8 virtual screening software, the target was docked against a library of natural compounds obtained from edible African plants. The compound, 2-({3-[(3,5-dichlorobenzyl) amino] propyl} amino) quinolin-4(1H)-one (OOU) which is a co-crystallized ligand with the target was used as the reference compound. Screening of the molecular descriptors of the compounds for bioavailability, pharmacokinetic properties, and bioactivity was performed using the SWISSADME, pkCSM, and Molinspiration web servers respectively. The Fpocket and PLIP webservers were used to perform the analyses of the binding pockets and the protein ligand interactions. Analysis of the time-resolved trajectories of the Apo and Holo forms of the target was performed using the Galaxy and MDWeb servers. The lead compounds, Strophanthidin and Isopteropodin are present in Corchorus olitorius and Uncaria tomentosa (Cat's-claw) plants respectively. Isopteropodin had a binding affinity score of -8.9 kcal / ml with the target and had 17 anti-correlating residues in Pocket 1 after molecular dynamics simulation. The complex formed by Isopteropodin and the target had a total RMSD of 4.408 and a total RMSF of 9.8067. However, Strophanthidin formed 3 hydrogen bonds with the target at ILE21, GLY262 and LEU294, and induced a total RMSF of 5.4541 at Pocket 1. Overall, Isopteropodin and Strophanthidin were found to be better drug candidates than OOU and they showed potentials to inhibit the Brucella melitensis Methionyl-tRNA synthetase at Pocket 1, hence abilities to treat brucellosis. In-vivo and in-vitro investigations are needed to further evaluate the efficacy and toxicity of the lead compounds.
Sections du résumé
BACKGROUND
Brucellosis is an infectious disease caused by bacteria of the genus Brucella. Although it is the most common zoonosis worldwide, there are increasing reports of drug resistance and cases of relapse after long term treatment with the existing drugs of choice. This study therefore aims at identifying possible natural inhibitors of Brucella melitensis Methionyl-tRNA synthetase through an in-silico approach.
METHODS
Using PyRx 0.8 virtual screening software, the target was docked against a library of natural compounds obtained from edible African plants. The compound, 2-({3-[(3,5-dichlorobenzyl) amino] propyl} amino) quinolin-4(1H)-one (OOU) which is a co-crystallized ligand with the target was used as the reference compound. Screening of the molecular descriptors of the compounds for bioavailability, pharmacokinetic properties, and bioactivity was performed using the SWISSADME, pkCSM, and Molinspiration web servers respectively. The Fpocket and PLIP webservers were used to perform the analyses of the binding pockets and the protein ligand interactions. Analysis of the time-resolved trajectories of the Apo and Holo forms of the target was performed using the Galaxy and MDWeb servers.
RESULTS
The lead compounds, Strophanthidin and Isopteropodin are present in Corchorus olitorius and Uncaria tomentosa (Cat's-claw) plants respectively. Isopteropodin had a binding affinity score of -8.9 kcal / ml with the target and had 17 anti-correlating residues in Pocket 1 after molecular dynamics simulation. The complex formed by Isopteropodin and the target had a total RMSD of 4.408 and a total RMSF of 9.8067. However, Strophanthidin formed 3 hydrogen bonds with the target at ILE21, GLY262 and LEU294, and induced a total RMSF of 5.4541 at Pocket 1.
CONCLUSION
Overall, Isopteropodin and Strophanthidin were found to be better drug candidates than OOU and they showed potentials to inhibit the Brucella melitensis Methionyl-tRNA synthetase at Pocket 1, hence abilities to treat brucellosis. In-vivo and in-vitro investigations are needed to further evaluate the efficacy and toxicity of the lead compounds.
Identifiants
pubmed: 35312681
doi: 10.1371/journal.pntd.0009799
pii: PNTD-D-21-01333
pmc: PMC8970508
doi:
Substances chimiques
Anti-Bacterial Agents
0
Ligands
0
Methionine-tRNA Ligase
EC 6.1.1.10
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0009799Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
PLoS Negl Trop Dis. 2021 Jan 7;15(1):e0008977
pubmed: 33411798
Acta Crystallogr D Struct Biol. 2016 Oct 1;72(Pt 10):1119-1129
pubmed: 27710933
J Med Chem. 2009 Nov 12;52(21):6752-6
pubmed: 19827778
Sci Rep. 2018 Jun 4;8(1):8538
pubmed: 29867163
Sci Rep. 2015 Jun 09;5:11090
pubmed: 26057345
BMC Infect Dis. 2004 Jun 23;4:18
pubmed: 15214959
Bioinformatics. 2012 May 1;28(9):1278-9
pubmed: 22437851
Drug Discov Today. 2011 Jan;16(1-2):65-72
pubmed: 21074634
Nucleic Acids Res. 2015 Jul 1;43(W1):W443-7
pubmed: 25873628
Nucleic Acids Res. 2016 Jan 4;44(D1):D1202-13
pubmed: 26400175
PLoS Negl Trop Dis. 2014 Jul 24;8(7):e3008
pubmed: 25058178
Eur J Pharm Sci. 2014 Jun 2;56:120-30
pubmed: 24576578
EXCLI J. 2016 Feb 12;15:113-8
pubmed: 27047321
Int J Med Sci. 2011 Mar 03;8(3):198-202
pubmed: 21448305
Int J Environ Res Public Health. 2018 Jun 17;15(6):
pubmed: 29914203
Methods Mol Biol. 2015;1263:243-50
pubmed: 25618350
Infect Ecol Epidemiol. 2012;2:
pubmed: 23240071
Curr Protoc Bioinformatics. 2013 Jun;Chapter 3:Unit3.1
pubmed: 23749753
Skin Res Technol. 2021 May;27(3):299-308
pubmed: 33095948
Expert Opin Drug Saf. 2016;15(3):367-82
pubmed: 26680308
Acta Biochim Pol. 2001;48(2):337-50
pubmed: 11732605
Antimicrob Agents Chemother. 2017 Oct 24;61(11):
pubmed: 28848016
J Med Chem. 2015 Aug 13;58(15):5691-8
pubmed: 25799158
J Chem Inf Model. 2007 Nov-Dec;47(6):2408-15
pubmed: 17929911
Pharmacol Ther. 2013 Apr;138(1):103-41
pubmed: 23333322
Acta Crystallogr D Biol Crystallogr. 2010 Jan;66(Pt 1):12-21
pubmed: 20057044
Nucleic Acids Res. 2018 Jul 2;46(W1):W537-W544
pubmed: 29790989
Nucleic Acids Res. 2003 Jul 1;31(13):3316-9
pubmed: 12824316
J Immunol. 2003 Jun 1;170(11):5607-14
pubmed: 12759440
J Med Chem. 2015 May 14;58(9):4066-72
pubmed: 25860834
Antimicrob Resist Infect Control. 2017 Dec 28;6:130
pubmed: 29299304
Int J Infect Dis. 2008 Mar;12(2):157-61
pubmed: 17698385
J Ethnopharmacol. 2000 Feb;69(2):115-26
pubmed: 10687868
J Hepatol. 1997;26 Suppl 2:26-36
pubmed: 9204407
Biotechnol Adv. 2017 Jul 8;:
pubmed: 28694178
Nucleic Acids Res. 2000 Jan 1;28(1):235-42
pubmed: 10592235
J Cereb Blood Flow Metab. 2012 Nov;32(11):1959-72
pubmed: 22929442
Comp Immunol Microbiol Infect Dis. 2016 Aug;47:1-6
pubmed: 27477501
PLoS One. 2016 Aug 08;11(8):e0160350
pubmed: 27500735
Acta Pharmacol Sin. 2013 Mar;34(3):329-35
pubmed: 23459091
Sci Rep. 2017 Mar 03;7:42717
pubmed: 28256516
Emerg Infect Dis. 1997 Apr-Jun;3(2):213-21
pubmed: 9204307
J Med Chem. 2016 May 12;59(9):4035-61
pubmed: 26807648
Front Oncol. 2020 Jan 17;9:1469
pubmed: 32010609
Int J Mol Sci. 2020 Oct 11;21(20):
pubmed: 33050610
Front Comput Neurosci. 2018 Jun 01;12:34
pubmed: 29910719
One Health. 2021 Apr 27;13:100255
pubmed: 34027005
Pan Afr Med J. 2013 Nov 17;16:103
pubmed: 24876892
J S Afr Vet Assoc. 2013 Mar 06;84(1):E1-5
pubmed: 23718254
BMC Infect Dis. 2018 Jan 16;18(1):43
pubmed: 29338693
Phytochemistry. 1998 Dec;49(7):2097-101
pubmed: 9883596
Br J Clin Pharmacol. 2019 Oct;85(10):2213-2217
pubmed: 31219196
Nucleic Acids Res. 2014 Jul;42(Web Server issue):W252-8
pubmed: 24782522
Sci Rep. 2016 Mar 31;6:23690
pubmed: 27030511
Nucleic Acids Res. 2018 Jul 2;46(W1):W296-W303
pubmed: 29788355
Protein Eng. 2000 Jan;13(1):9-13
pubmed: 10679524
J Infect. 2006 Jul;53(1):e39-41
pubmed: 16249034
Bioinformation. 2017 Jan 20;13(1):8-16
pubmed: 28479744
Am J Cardiol. 1992 Jan 15;69(3):169-72
pubmed: 1731453
Front Oncol. 2020 Feb 11;10:121
pubmed: 32117768
Nucleic Acids Res. 2021 Jan 8;49(D1):D480-D489
pubmed: 33237286
Vet Microbiol. 2002 Dec 20;90(1-4):111-34
pubmed: 12414138
Proc Natl Acad Sci U S A. 2009 Jun 30;106(26):10505-10
pubmed: 19553204
J Clin Microbiol. 2004 Dec;42(12):5439-43
pubmed: 15583262
Int J Mol Sci. 2008 Oct;9(10):1961-76
pubmed: 19325729
J Vet Med Sci. 2013;75(8):1035-40
pubmed: 23545462
Bioinformatics. 2011 Feb 1;27(3):343-50
pubmed: 21134891
PLoS One. 2015 Jul 16;10(7):e0132532
pubmed: 26181775